Nice — I pulled recent market reports, company filings and industry press and compiled a concise, source-backed market brief for the Artificial Joints market (aka hip, knee, shoulder & other joint replacement implants). Below you’ll find multiple published market estimates (reports use different scopes), the items you asked for, and a paste-ready company reference table with company / parent revenues where publicly reported or clearly noted. I cite the most important sources so you can verify or dig deeper.

This versatile research report is presenting crucial details on market relevant information, harping on ample minute details encompassing a multi-dimensional market that collectively maneuver growth in the global Artificial Joints market.

This holistic report presented by the report is also determined to cater to all the market specific information and a take on business analysis and key growth steering best industry practices that optimize million-dollar opportunities amidst staggering competition in Artificial Joints market.

Read complete report at: https://www.thebrainyinsights.com/report/artificial-joints-market-14185

Artificial Joints Market — snapshot & headline estimates

global artificial hip & knee joints market was USD 12.57 billion (2023) and is projected to grow at a CAGR of ~2.8% (2024–2030).
reports a positive outlook for the joint replacement market and lists Zimmer Biomet, Johnson & Johnson (DePuy Synthes) and Stryker among the largest vendors. (Note: MarketsandMarkets definitions vary by report — some include services, instruments, implants and revision markets).
larger orthopedic-implant market reports place the wider orthopedic implants market (including spine, trauma, extremities) much higher (dozens of billions USD), so make sure you pick the scope (hip/knee only vs. full orthopedic implants) for any headline you use.

Recent developments

Robotics & digital workflows adoption: robotic-assisted knee and hip procedures, navigation and digital pre-planning are increasingly standard in advanced centers, improving precision and driving higher-value system sales and recurring instrument/consumable use.
Corporate moves & portfolio reshaping: ongoing strategic activity — e.g., Johnson & Johnson’s orthopaedics (DePuy Synthes) performance reported at ~USD 9.2B in 2024 and was a focus of recent corporate restructuring discussions — these large strategic moves reshape competitive dynamics.
Shift to outpatient & fast-track procedures: more joint replacements are moving to ambulatory surgery centers / short-stay pathways in many markets, changing demand for implants, instrumentation kits and service models.

Drivers

Demographics & disease burden: aging populations and rising osteoarthritis prevalence are the primary long-term demand drivers for hip and knee replacements. Grand View and other reports cite osteoarthritis incidence and geriatrics as core growth factors.
Technological innovation: robotic assistance, patient-matched implants, new biomaterials, and porous/3D-printed surfaces that improve osseointegration are pushing replacement volumes and ASPs (average selling prices).
Expansion of access in emerging markets: rising surgical capacity in APAC/Latin America (more trained surgeons, more OR capacity) creates volume opportunities.

Restraints

Reimbursement & pricing pressure: cost containment (public payers, DRG caps) and contracting pressure in major markets can slow unit growth or compress margins.
Clinical risks & recalls: product recalls, implant failures or litigation (implant-related safety issues) can damage vendor sales and slow adoption of specific technologies.
Surgeon availability & training: shortage of trained orthopedic surgeons or limited access to robotic systems in low-resource settings limits adoption despite epidemiological need.

Regional segmentation analysis

North America: large per-procedure spending, early adoption of robotics and new implants; strong hospital & ASC markets.
Europe: mature markets with strong public payers; uptake of premium technologies varies by country and reimbursement.
Asia-Pacific: fastest volume growth potential — expanding procedure capacity in China, India and SE Asia, plus elective volume increases as access improves.

Emerging trends

3D printing / additive manufacturing for custom and revision implants (porous structures, patient-specific geometries).
Sensor-enabled & “smart” implants (early stage) for objective post-op monitoring and load sensing.
Robotic and navigation platforms expanding from knees into hips, shoulders and extremities — vendors increasingly bundle hardware + consumables + software subscriptions.

Top use cases

Primary total knee arthroplasty (TKA) — largest single procedure volume in many markets.
Total hip arthroplasty (THA) — large market with premium segment (ceramic bearings, large-head technology).
Revision arthroplasty & trauma/external fixation crossover — higher ASPs and specialized implants for complex cases.

Major challenges

Long regulatory & clinical validation cycles for novel materials and smart implants (slows time-to-market).
Price sensitivity in public systems and emerging markets — vendors must balance innovation with cost competitiveness.

Attractive opportunities

Outpatient/ASC-oriented implant kits and small-footprint instrumentation to capture fast-track cases.
Aftermarket & services (instrumentation leasing, navigation/robot subscriptions, instrument reprocessing and warranty services) for recurring revenue.
Emerging-market penetration with tiered product lines and local partnerships for volume adoption.

Key factors of market expansion

Aging population & OA burden, wider surgical capacity, faster adoption of robotics & 3D-printed implants, reimbursement environment, and proven long-term clinical outcomes that justify uptake. Macroeconomic cycles and safety events will materially influence the growth path.

Company reference table — major players & values (parent / reported figures)

Important: many companies do not disclose “artificial joints” as a separate public revenue line — numbers below are parent / franchise totals or widely published orthopedics/medical device figures. I mark when an item is the orthopaedics franchise (not implants-only).

Stryker Corporation — Parent net sales 2024: USD 22.6 billion (2024). Stryker’s Orthopaedics business contributed ~USD 9.1 billion of that in 2024 (orthopaedics segment lines noted in Stryker filings).
Johnson & Johnson — DePuy Synthes (Orthopaedics) — Orthopaedics / DePuy sales 2024: ~USD 9.2 billion (reported as the orthopaedics franchise within J&J). J&J/DePuy is a leading hip & knee supplier.
Zimmer Biomet — Net sales 2024: USD 7.679 billion (2024) (Zimmer Biomet is a top orthopedics/implant vendor).
Smith & Nephew — Group revenue 2024: USD 5.81 billion (2024) — active in hips, knees, trauma & revision, and orthopedics instruments.
DePuy / Johnson & Johnson — (see DePuy note above).
Exactech, Inc. — Recent reported revenue range / public estimates: ~USD 250–270 million (company has been through restructuring and asset sales; Exactech remains a mid-tier orthopedics implant player focused on knees, hips and extremities).
LimaCorporate, Corin, Wright Medical (now integrated into Stryker), Aesculap/B. Braun, ConforMIS (if still active), and smaller specialists — significant regional / niche players (some private; many do not disclose separate joint-line revenues). Use their annual reports or company pages for product & regional footprints.